Non-viral delivery of RNA interference targeting cancer cells in cancer gene therapy

Current Gene Therapy

Volumn 12, Issue 4, 2012, Pages 275-284

  Huang, Pin I ^a,c,d   Lo, Wen Liang ^b,d,e   Cherng, Jong Yuh ^d,f   Chien, Yueh ^a,b,d   Chiou, Guang Yuh ^b,d   Chiou, Shih Hwa ^a,b,d  

^a Institute of Clinical Medicine   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c Cancer Center   (Taiwan)

^d Cancer Center ^*  (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Cancer gene therapy; Liposomes; MicroRNA; Non viral delivery; Nuclear localization signal; Polymers; RNA interference; SiRNA

Indexed keywords

ADAMANTANE; ALN VSP02; ANTINEOPLASTIC AGENT; ATU 027; CALAA 01; CARBOPLATIN; CYCLODEXTRIN; DOCETAXEL; EGEN 001; HYALURONIC ACID; INTERLEUKIN 12; LIPOSOME; MACROGOL; MICRORNA; MICRORNA 143; MICRORNA 145; MICRORNA 33A; MICRORNA 34A; MICRORNA 7; NANOPARTICLE; PLASMID DNA; POLYCATION; POLYETHYLENEIMINE; POLYMER; POLYURETHAN; RONDEL; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TKM 080301; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; COLON CANCER; CYTOTOXICITY; DNA VECTOR; DOSE RESPONSE; DRUG FORMULATION; DRUG TARGETING; FEVER; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HYPOKALEMIA; INJECTION SITE REACTION; LIVER CANCER; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG METASTASIS; MELANOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; NUCLEAR LOCALIZATION SIGNAL; OVARY CANCER; PERITONEUM CANCER; PROSTATE CANCER; REVIEW; RNA INTERFERENCE; SOLID TUMOR; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LIPOSOMES; NANOPARTICLES; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84864538439     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312802083576     Document Type: Review

References (96)

1. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4:346-58.
2. Elsabahy M, Nazarali A, Foldvari M. Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv. 2011;8:235-44.
3. Veiseh O, Kievit FM, Fang C, et al. Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials. 2010;31:8032-42.
4. Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM. Octafunctional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials. 2012;33:583-91.
5. Jiang HL, Xu CX, Kim YK, et al. The suppression of lung tumorigenesis by aerosol-delivered folate-chitosan-graftpolyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway. Biomaterials. 2009;30:5844-52.
6. Kaneda MM, Sasaki Y, Lanza GM, Milbrandt J, Wickline SA. Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions. Biomaterials. 2010;31:3079-86.
7. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6:443-53.
8. Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest. 2007;117:3633-41.
9. Caplen NJ. Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther. 2004;11:1241-8.
10. Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov. 2004;3:318-29.
11. Shankar P, Manjunath N, Lieberman J. The prospect of silencing disease using RNA interference. JAMA. 2005;293:1367-73.
12. Tuschl T, Zamore PD, Lehmann R, Bartel DP, Sharp PA. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 1999;13:3191-7.
13. Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science. 1999;286:950-2.
14. Robb GB, Brown KM, Khurana J, Rana TM. Specific and potent RNAi in the nucleus of human cells. Nat Struct Mol Biol. 2005;12:133-7.
15. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350-5.
16. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-97.
17. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522-31.
18. Finnegan EJ, Matzke MA. The small RNA world. J Cell Sci. 2003;116:4689-93.
19. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789-99.
20. Ryther RC, Flynt AS, Phillips JA, 3rd, Patton JG. siRNA therapeutics: big potential from small RNAs. Gene Ther. 2005;12:5-11.
21. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550-3.
22. Chen J, Wall NR, Kocher K, et al. Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J Clin Invest. 2004;113:1784-91.
23. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer. Surgery. 2004;136:261-9.
24. Zhou Z, Zhu JS, Xu ZP, Zhang Q. Lentiviral vector-mediated siRNA knockdown of the YAP gene inhibits growth and induces apoptosis in the SGC7901 gastric cancer cell line. Mol Med Report. 2011;4:1075-82.
25. Li XY, Lai YK, Zhang JF, et al. Lentivirus-mediated RNA interference targeting Bax inhibitor-1 suppresses ex vivo cell proliferation and in vivo tumor growth of nasopharyngeal carcinoma. Hum Gene Ther. 2011;22:1201-8.
26. Dharmapuri S, Peruzzi D, Marra E, et al. Intratumor RNA interference of cell cycle genes slows down tumor progression. Gene Ther. 2011;18:727-33.
27. Li H, Fu X, Chen Y, et al. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology. 2005;128:2029-41.
28. Xu D, McCarty D, Fernandes A, Fisher M, Samulski RJ, Juliano RL. Delivery of MDR1 small interfering RNA by selfcomplementary recombinant adeno-associated virus vector. Mol Ther. 2005;11:523-30.
29. Chen CC, Chang CM, Sun CP, et al. Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus. Gene Ther. 2012;19:25-33.
30. Tsuno T, Mejido J, Zhao T, et al. BID is a Critical Factor Controlling Cell Viability Regulated by IFN-alpha. J Immunother. 2012;35:23-31.
31. Kleinman ME, Kaneko H, Cho WG, et al. Short-interfering RNAs Induce Retinal Degeneration via TLR3 and IRF3. Mol Ther. 2012;20:101-8.
32. Olejniczak M, Polak K, Galka-Marciniak P, Krzyzosiak WJ. Recent Advances in Understanding of the Immunological Off-Target Effects of siRNA. Curr Gene Ther. 2011;11:532-43.
33. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137:1005-17.
34. Esquela-Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 2008;7:759-64.
35. Trang P, Medina PP, Wiggins JF, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene. 2010;29:1580-7.
36. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther. 2010;18:1650-6.
37. Akao Y, Nakagawa Y, Hirata I, et al. Role of anti-oncomirs miR-143 and-145 in human colorectal tumors. Cancer Gene Ther. 2010;17:398-408.
38. Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011;71:5214-24.
39. Tan PH, Janes SE, Handa AI, Friend PJ. More trouble ahead; is gene therapy coming of age? Expert Opin Biol Ther. 2008;8:561-7.
40. Lehrman S. Virus treatment questioned after gene therapy death. Nature. 1999;401:517-8.
41. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 2010;31:358-65.
42. Liu F, Qi H, Huang L, Liu D. Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration. Gene Ther. 1997;4:517-23.
43. Liu Y, Mounkes LC, Liggitt HD, et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol. 1997;15:167-73.
44. Yano J, Hirabayashi K, Nakagawa S, et al. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res. 2004;10:7721-6.
45. Santel A, Aleku M, Keil O, et al. RNA interference in the mouse vascular endothelium by systemic administration of siRNAlipoplexes for cancer therapy. Gene Ther. 2006;13:1360-70.
46. Pal A, Ahmad A, Khan S, et al. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol. 2005;26:1087-91.
47. Chien PY, Wang J, Carbonaro D, et al. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther. 2005;12:321-8.
48. Sutton D, Kim S, Shuai X, et al. Efficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. Int J Nanomedicine. 2006;1:155-62.
49. Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A. 1995;92:7297-301.
50. Fischer D, Bieber T, Li Y, Elsasser HP, Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res. 1999;16:1273-9.
51. Gosselin MA, Guo W, Lee RJ. Efficient gene transfer using reversibly cross-linked low molecular weight polyethylenimine. Bioconjug Chem. 2001;12:989-94.
52. Liang B, He ML, Xiao ZP, et al. Synthesis and characterization of folate-PEG-grafted-hyperbranched-PEI for tumor-targeted gene delivery. Biochem Biophys Res Commun. 2008;367:874-80.
53. Nguyen HK, Lemieux P, Vinogradov SV, et al. Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents. Gene Ther. 2000;7:126-38.
54. Neu M, Germershaus O, Behe M, Kissel T. Bioreversibly crosslinked polyplexes of PEI and high molecular weight PEG show extended circulation times in vivo. J Control Release. 2007;124:69-80.
55. Tang GP, Zeng JM, Gao SJ, et al. Polyethylene glycol modified polyethylenimine for improved CNS gene transfer: effects of PEGylation extent. Biomaterials. 2003;24:2351-62.
56. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release. 2008;129:107-16.
57. Wu Y, Wang W, Chen Y, et al. The investigation of polymersiRNA nanoparticle for gene therapy of gastric cancer in vitro. Int J Nanomedicine. 2010;5:129-36.
58. Guan J, Fujimoto KL, Sacks MS, Wagner WR. Preparation and characterization of highly porous, biodegradable polyurethane scaffolds for soft tissue applications. Biomaterials. 2005;26:3961-71.
59. Shau MD, Tseng SJ, Yang TF, Cherng JY, Chin WK. Effect of molecular weight on the transfection efficiency of novel polyurethane as a biodegradable gene vector. J Biomed Mater Res A. 2006;77:736-46.
60. Tseng SJ, Tang SC, Shau MD, Zeng YF, Cherng JY, Shih MF. Structural characterization and buffering capacity in relation to the transfection efficiency of biodegradable polyurethane. Bioconjug Chem. 2005;16:1375-81.
61. Hung WC, Shau MD, Kao HC, Shih MF, Cherng JY. The synthesis of cationic polyurethanes to study the effect of amines and structures on their DNA transfection potential. J Control Release. 2009;133:68-76.
62. Liu XY, Ho WY, Hung WJ, Shau MD. The characteristics and transfection efficiency of cationic poly (ester-co-urethane)-short chain PEI conjugates self-assembled with DNA. Biomaterials. 2009;30:6665-73.
63. Yang YP, Chien Y, Chiou GY, et al. Inhibition of cancer stem celllike properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials. 2012;33:1462-76.
64. Kabanov AV, Batrakova EV, Sriadibhatla S, Yang Z, Kelly DL, Alakov VY. Polymer genomics: shifting the gene and drug delivery paradigms. J Control Release. 2005;101:259-71.
65. Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev. 2007;59:164-82.
66. Merkel OM, Librizzi D, Pfestroff A, et al. Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-gpoly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. J Control Release. 2009;138:148-59.
67. Merkel OM, Beyerle A, Beckmann BM, et al. Polymer-related offtarget effects in non-viral siRNA delivery. Biomaterials. 2011;32:2388-98.
68. Dean DA, Strong DD, Zimmer WE. Nuclear entry of nonviral vectors. Gene Ther. 2005;12:881-90.
69. Liu G, Li D, Pasumarthy MK, et al. Nanoparticles of compacted DNA transfect postmitotic cells. J Biol Chem. 2003;278:32578-86.
70. Mann A, Thakur G, Shukla V, Ganguli M. Peptides in DNA delivery: current insights and future directions. Drug Discov Today. 2008;13:152-60.
71. Munkonge FM, Dean DA, Hillery E, Griesenbach U, Alton EW. Emerging significance of plasmid DNA nuclear import in gene therapy. Adv Drug Deliv Rev. 2003;55:749-60.
72. Zanta MA, Belguise-Valladier P, Behr JP. Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad Sci U S A. 1999;96:91-6.
73. Lange A, Mills RE, Lange CJ, Stewart M, Devine SE, Corbett AH. Classical nuclear localization signals: definition, function, and interaction with importin alpha. J Biol Chem. 2007;282:5101-5.
74. Kalderon D, Richardson WD, Markham AF, Smith AE. Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature. 1984;311:33-8.
75. Won YW, Lim KS, Kim YH. Intracellular organelle-targeted nonviral gene delivery systems. J Control Release. 2011;152:99-109.
76. Min SH, Kim DM, Kim MN, et al. Gene delivery using a derivative of the protein transduction domain peptide, K-Antp. Biomaterials. 2010;31:1858-64.
77. Cheng FY, Wang SP, Su CH, et al. Stabilizer-free poly(lactide-coglycolide) nanoparticles for multimodal biomedical probes. Biomaterials. 2008;29:2104-12.
78. Chen J, Yu Z, Chen H, Gao J, Liang W. Transfection efficiency and intracellular fate of polycation liposomes combined with protamine. Biomaterials. 2011;32:1412-8.
79. Wang HY, Li C, Yi WJ, et al. Targeted delivery in breast cancer cells via iodine: nuclear localization sequence conjugate. Bioconjug Chem. 2011;22:1567-75.
80. Kang B, Mackey MA, El-Sayed MA. Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis. J Am Chem Soc. 2010;132:1517-9.
81. Lo WL, Chien Y, Chiou GY, et al. Nuclear localization signalenhanced RNA interference of EZH2 and Oct4 in the eradication of head and neck squamous cell carcinoma-derived cancer stem cells. Biomaterials. 2012;33:3693-709.
82. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464:1067-70.
83. Aleku M, Schulz P, Keil O, et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 2008;68:9788-98.
84. Leenders F, Mopert K, Schmiedeknecht A, et al. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J. 2004;23:3303-13.
85. Santel A, Aleku M, Roder N, et al. Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res. 2010;16:5469-80.
86. Strumberg D, Schultheis B, Traugott U, et al. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther. 2012;50:76-8.
87. Landen CN, Jr., Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005;65:6910-8.
88. Landen CN, Merritt WM, Mangala LS, et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006;5:1708-13.
89. Merritt WM, Lin YG, Spannuth WA, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008;100:359-72.
90. Rai K, Takigawa N, Ito S, et al. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther. 2011;10:1720-7.
91. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2005;12:461-6.
92. Grzelinski M, Urban-Klein B, Martens T, et al. RNA interferencemediated gene silencing of pleiotrophin through polyethyleniminecomplexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther. 2006;17:751-66.
93. Hobel S, Koburger I, John M, et al. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med. 2010;12:287-300.
94. Park K, Lee MY, Kim KS, Hahn SK. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate. Biomaterials. 2010;31:5258-65.
95. Lu ZX, Liu LT, Qi XR. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy. Int J Nanomedicine. 2011;6:1661-73.
96. Chiou GY, Cherng JY, Hsu HS, et al. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelialmesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J Control Release. 2012;159:240-50.